Xiamen Amoytop Biotech Co., Ltd.: history, ownership, mission, how it works & makes money

From its founding in 1996 and the launch of China's first domestic molgramostim in 1997 to recent product approvals like the long-acting G-CSF Tuopui Feigesi (Peijin) in 2023 and Yipei Growth Hormone in May 2025, Xiamen Amoytop Biotech Co., Ltd. (SSE: 688278) has built a focused recombinant-protein franchise that combines clinical ambition with market traction - a company with a market capitalization of 34.29 billion CNY (as of Dec 12, 2025), 408.19 million shares outstanding and a P/E of 36.37, generating 2.82 billion CNY in operating income in 2024 (up 34.13%) and net profit of 828 million CNY (+49%) as it channels roughly 32% of revenue into R&D, scales sales of flagship products like Pegasbin for chronic hepatitis B, expands via collaborations with Aligos and Drug Farm and strategic deals such as the Jiutian Cayman acquisition, and presents a dividend of 0.62 CNY per share (yield 0.74%) amid a 52-week trading range of 66.00-93.52 CNY and a risk profile indicated by a beta of -0.23, all of which make its trajectory, commercial model and R&D pipeline essential reading for investors and industry watchers alike.

Xiamen Amoytop Biotech Co., Ltd. (688278.SS): Intro

• Founding year: 1996; IPO: listed on Shanghai STAR Market (ticker 688278.SS).
• Early leadership: 1997 - first and largest domestic launch of Molgramostim in China, establishing recombinant protein production capabilities.
• R&D and manufacturing focus: recombinant proteins, PEGylation/half-life extension technologies and clinical development across hematology, endocrinology and hepatology.

• Listed entity on Shanghai STAR Market (688278.SS) with public float and institutional investors participating post‑IPO.
• Corporate governance typical of PRC-listed biotechs: board of directors, management team with scientific leadership, and R&D hubs in Xiamen.

• Mission: develop and commercialize innovative recombinant protein therapeutics to address hematologic, endocrine and hepatic diseases in China and Greater China.
• Strategy: leverage in‑house protein engineering and long‑acting technologies, pursue registration and commercialization in China, and partner with international biotech firms for combination trials and regional rights.

• R&D: discovery and optimization of recombinant proteins and long‑acting formulations (e.g., PEGylation, fusion proteins).
• Clinical development: in‑house and partnered clinical trials (e.g., collaboration with Aligos for HBV combination therapy).
• Manufacturing: GMP recombinant protein production capacity enabling internal supply and potential contract manufacturing.
• Regulatory pathway: pursue NMPA approvals for biologics and new long‑acting formulations; achieved national class 1 approval for Peijin (2023) and market approval for Yipeisheng (May 2025).
• Commercialization: direct sales in China for approved biologics; partnership/licensing deals for combination therapies and regional development (e.g., option agreement with Drug Farm for DF‑006).

• Product sales: marketed recombinant biologics and long‑acting therapeutics (e.g., Peijin, Yipeisheng) generate primary revenue.
• Collaborations and licensing: option agreements, clinical collaborations and milestone/license fees (e.g., Aligos collaboration, Drug Farm option).
• Contract manufacturing or supply agreements: leveraging manufacturing capacity to supply partners or third parties.
• Potential future royalties: from out‑licensed assets or partnered commercialization in Greater China and beyond.

• Molgramostim - early domestic recombinant product (launched 1997).
• Tuopui Feigesi Injection (Peijin) - long‑acting human G‑CSF; national class 1 therapeutic biologic (2023).
• Yipei Growth Hormone Injection (Yipeisheng) - long‑acting growth hormone (market approval May 2025).
• Pipeline collaborations - ALG‑000184 combination trial with Aligos (July 2024); DF‑006 option with Drug Farm (May 2025).

• Aligos Therapeutics, Inc. - clinical trial collaboration to evaluate ALG‑000184 + PEGBING® in chronic hepatitis B patients (July 2024).
• Drug Farm - option agreement to collaborate on DF‑006 for HBV and hepatocellular carcinoma in Greater China (May 2025).

Xiamen Amoytop Biotech Co., Ltd. (688278.SS): History

• Public listing: Shanghai Stock Exchange (688278.SS)
• Core activities: API manufacturing, chemical intermediates, custom synthesis, contract research & manufacturing (CRAM)
• Strategic moves: capacity expansions, compliance upgrades for GMP, and increased export orientation

Ownership Structure

• Publicly listed with free-float and institutional shareholders; exact major shareholder percentages vary over reporting periods.
• Retail vs. institutional mix influenced by domestic biotech investor interest and strategic corporate investors.

Mission

• Provide high-quality active pharmaceutical ingredients and intermediates to global pharma and specialty chemical customers.
• Integrate R&D, process optimization and compliant manufacturing to support downstream drug development and supply chains.

How It Works & Makes Money

• Product sales: APIs and chemical intermediates sold to pharmaceutical companies, generic manufacturers and specialty chemical firms.
• Custom synthesis/contract manufacturing: revenue from bespoke synthesis, scale-up and toll manufacturing contracts.
• R&D services: contract research and optimization projects with milestone and service fees.
• Export sales: international customers contribute via cross-border contracts and long-term supply agreements.

Xiamen Amoytop Biotech Co., Ltd. (688278.SS): Ownership Structure

• Core mission: develop cytokine- and recombinant protein-based therapies to address unmet needs in immunology and oncology.
• Clinical focus: chronic hepatitis B, oncology immunotherapy, and systemic immune modulation.
• R&D orientation: advance clinical cures through translational research and multi-party collaborations.
• Strategic partnerships: technology and development alliances (e.g., Aligos Therapeutics, Drug Farm) to enhance pipeline and global reach.

• Pipeline breadth: multiple recombinant protein candidates with several programs in clinical development (preclinical → Phase I/II/III progression).
• Clinical emphasis: prioritized chronic hepatitis B programs aiming for functional cure approaches alongside oncology/immunotherapy candidates.
• R&D investment philosophy: sustained reinvestment into clinical trials and biologics manufacturing capacity to support late-stage development.

• How it makes money:
  • Proprietary product sales (upon commercialization of lead biologics).
  • Out-licensing and co-development milestones and royalties from partners.
  • Collaborative R&D fees and milestone payments from strategic alliances.
• Ownership highlights:
  • Public float on the Shanghai STAR Market provides institutional and retail investor participation.
  • Founders, executives, and strategic investors typically hold significant blocks alongside institutional shareholders.

Xiamen Amoytop Biotech Co., Ltd. (688278.SS): Mission and Values

• End-to-end recombinant protein development: target discovery → expression system optimization (CHO/Escherichia coli) → process development → scale-up production → regulatory submission → commercial supply.
• Multiple product formats: injectable biologics (long-acting pegylated proteins, standard recombinant growth factors, cytokines) and APIs/reagents for diagnostic and therapeutic use.
• Dual-channel commercialization: direct sales and partnerships/licensing domestically in China, plus export sales and OEM/API supply to international pharma companies.
• Capitalization and growth via equity markets: listing on the SSE STAR Market provides access to growth capital targeted at accelerating clinical programs and expanding biologics manufacturing capacity.
• Strategic M&A to aggregate capabilities: planned acquisition of Jiutian Cayman to integrate additional technology platforms and expand product pipeline and manufacturing scale.

• Pegsomatropin injection (long-acting growth hormone)
• Pegfilgrastim injection (long-acting G-CSF for neutropenia prevention)
• Molgramostim and filgrastim (GM-CSF and G-CSF formulations)
• Oprelvekin (IL-11 analog for thrombocytopenia management)
• APIs and reagents for viral hepatitis, oncology-supportive therapies, and immunotherapy research.

• Product sales: finished-dose biologics (highest margin once commercialized).
• API and reagent supply: steady recurring revenue from B2B contracts and international customers.
• License / partnering fees: milestone payments and royalties from out-licensed programs.
• Platform services: process development and custom manufacture for external biotech clients.

• R&D budget allocation: sustained high reinvestment - R&D equals 32% of revenue, funding preclinical and clinical development across pegylated and native protein candidates.
• Pipeline focus: biosimilars and novel long-acting biologics addressing neutropenia, growth disorders, and immune support in oncology.
• Manufacturing-led innovation: investing in single-use bioreactors, downstream purification, and analytical platforms to reduce cost of goods and accelerate time-to-market.

• Advantages: integrated capabilities from molecule to market, STAR Market access to equity capital, targeted M&A to build specialized technologies.
• Risks: regulatory approval timeline variability, biosimilar price competition, and execution risk in large international supply contracts and M&A integration.

Xiamen Amoytop Biotech Co., Ltd. (688278.SS): How It Works

• Core mission: develop affordable, high-quality recombinant biologics for major chronic and infectious diseases while building integrated upstream and downstream biomanufacturing capabilities.
• Ownership: publicly listed on the Shanghai STAR Market (ticker 688278.SS); mix of institutional investors, management holdings and public float.
• Strategic positioning: vertical integration across R&D, GMP manufacturing, and commercialization to control cost, quality, and time-to-market.

• R&D platform: recombinant protein expression systems (E. coli, yeast, mammalian) for therapeutic proteins and biosimilars.
• Manufacturing: GMP-compliant fermentation, purification, formulation and fill-finish capabilities that serve both internal products and CDMO customers.
• Commercialization: in-house sales force and hospital/clinic distribution channels for marketed products; licensing and co-development partnerships for broader market access.

• Direct product sales: primary revenue from recombinant protein drugs (notably Pegasbin for chronic hepatitis B) and related APIs sold domestically and in select export markets.
• Commercialization of proprietary drugs: Pegasbin functions as a first-line therapy for chronic hepatitis B and is a material contributor to 2024 revenue growth.
• CDMO and API manufacturing: contract manufacturing and sales of APIs and intermediates to pharmaceutical clients.
• Collaborations and licensing: strategic partnerships, licensing fees and milestone payments from co-development agreements that supplement product sales.

• Total operating income: 2.82 billion CNY (34.13% YoY growth).
• Net profit attributable to parent company: 828 million CNY (49% YoY growth).
• EPS: 2.03 CNY, reflecting improved margin capture from product commercialization.
• Growth drivers: Pegasbin commercialization scale-up, higher-margin proprietary sales, and income from strategic collaborations/licensing.

• Proprietary drug sales - higher ASPs (average selling prices) and improving gross margins as scale increases.
• API/CDMO services - stable volume contracts that provide base revenue and utilization leverage for fixed-cost manufacturing assets.
• Licensing/collaboration - non-recurring but high-margin inflows that de-risk development spend and accelerate market penetration.

Xiamen Amoytop Biotech Co., Ltd. (688278.SS): How It Makes Money

• Core product sales: marketed recombinant protein drugs for infectious and chronic diseases, led by CHB-focused assets.
• Contract development and manufacturing (CDMO) services: production and process development for third parties.
• Out-licensing and milestone/license fees from partners (e.g., Aligos Therapeutics, Drug Farm).
• M&A and platform monetization: anticipated contribution from Jiutian Cayman acquisition to expand technical capabilities and pipeline value.

• Market position: a significant player in China's recombinant protein segment with above-market revenue growth and a specialized CHB focus.
• Future outlook: innovation-led expansion via partnerships (Aligos, Drug Farm), platform enhancement through Jiutian Cayman, and diversified revenue streams supporting continued top-line growth.